Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biom...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2011-09-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1422-0067/12/9/5895/ |
| id |
doaj-dd5772c49a604ce7907864a14ed80860 |
|---|---|
| record_format |
Article |
| spelling |
doaj-dd5772c49a604ce7907864a14ed808602020-11-24T23:30:08ZengMDPI AGInternational Journal of Molecular Sciences1422-00672011-09-011295895590710.3390/ijms12095895Looking to the Future: Biomarkers in the Management of Pancreatic AdenocarcinomaKaren E. MulderJennifer L. SpratlinThe incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation.http://www.mdpi.com/1422-0067/12/9/5895/pancreatic adenocarcinomahENT1hCNT3SPARCcDKbiomarkerclinical trialsgemcitabineoxaliplatin |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Karen E. Mulder Jennifer L. Spratlin |
| spellingShingle |
Karen E. Mulder Jennifer L. Spratlin Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma International Journal of Molecular Sciences pancreatic adenocarcinoma hENT1 hCNT3 SPARC cDK biomarker clinical trials gemcitabine oxaliplatin |
| author_facet |
Karen E. Mulder Jennifer L. Spratlin |
| author_sort |
Karen E. Mulder |
| title |
Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma |
| title_short |
Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma |
| title_full |
Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma |
| title_fullStr |
Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma |
| title_full_unstemmed |
Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma |
| title_sort |
looking to the future: biomarkers in the management of pancreatic adenocarcinoma |
| publisher |
MDPI AG |
| series |
International Journal of Molecular Sciences |
| issn |
1422-0067 |
| publishDate |
2011-09-01 |
| description |
The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation. |
| topic |
pancreatic adenocarcinoma hENT1 hCNT3 SPARC cDK biomarker clinical trials gemcitabine oxaliplatin |
| url |
http://www.mdpi.com/1422-0067/12/9/5895/ |
| work_keys_str_mv |
AT karenemulder lookingtothefuturebiomarkersinthemanagementofpancreaticadenocarcinoma AT jenniferlspratlin lookingtothefuturebiomarkersinthemanagementofpancreaticadenocarcinoma |
| _version_ |
1725542595808985088 |